Hormones and breast cancer

Area of Science:

• Endocrinology
• Oncology
• Epidemiology

Background:

• The relationship between endogenous and exogenous hormones and breast cancer development is not fully understood.
• Estrogens and androgens are implicated in breast cancer etiology.
• Research is ongoing to clarify hormone exposure risks.

Purpose of the Study:

• To review and synthesize evidence on the association between hormone use and breast cancer risk.
• To evaluate the impact of oral contraceptives and hormone replacement therapy on breast cancer incidence.

Main Methods:

• Review of numerous observational studies and meta-analyses.
• Analysis of data from large cohort studies like the Cancer and Steroid Hormone Study.
• Synthesis of findings from studies on oral contraceptive use, hormone replacement therapy, and pregnancy.

Main Results:

• Some studies indicate a twofold increased risk of early-onset breast cancer with 10 years of oral contraceptive use.
• The Cancer and Steroid Hormone Study found no association between oral contraceptive use and breast cancer in women up to age 54.
• Meta-analysis of hormone replacement therapy showed no increased risk with ever-use (RR, 1.02; 95% CI, 0.93-1.12).
• Long-term oral contraceptive use (>10 years) showed a small increased risk (RR, 1.23; 95% CI, 1.08-1.40).
• Pregnancy shortly before or after breast cancer diagnosis did not adversely affect prognosis.

Conclusions:

• The overall association between hormone use and breast cancer risk requires careful consideration of various study results.
• Long-term oral contraceptive use may confer a small increased risk.
• Hormone replacement therapy shows no significant increased risk for breast cancer.
• The decision to use hormones in high-risk women or those with a history of breast cancer should weigh benefits against risks.